在转移性结直肠癌中，氟尿嘧啶/亚叶酸与奥沙利铂交替使用，以及氟尿嘧啶/亚叶酸与伊立替康交替使用。
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
作者信息
Petrioli R, Sabatino M, Fiaschi A I, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G
机构信息
Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy.
出版信息
Br J Cancer. 2004 Jan 26;90(2):306-9. doi: 10.1038/sj.bjc.6601521.
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
共有41例转移性结直肠癌（CRC）患者接受替加氟/尿嘧啶（UFT）+亚叶酸钙（LV）+奥沙利铂与UFT/LV+伊立替康交替治疗。总缓解率为58.5%（95%置信区间，42.2 - 73.3%），无进展生存期的中位数为8.8个月。无4级毒性反应；12例患者（29%）出现3级腹泻。无手足综合征病例。这种交替方案在转移性CRC患者的一线治疗中似乎有效且耐受性良好。
Zotero 插件